MetaCap

McKesson Financial Ratios

NYSE: MCKHealth CareOther PharmaceuticalsUSD

938.84+8.59 (+0.92%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

McKesson ratio analysis

McKesson earned a net margin of 1.2% in FY 2026, up from 0.9% a year earlier. Gross margin was 3.6% compared with a median of 5.1% over the prior 9 years. At the end of FY 2026, MCK traded at 23.0 times earnings; across the 9 fiscal years shown, its year-end P/E ranged from 6.5 to 688.6, with a median of 25.4.

Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.

Summary generated from market data by MetaCap's automated system. Methodology

McKesson financial ratios (annual)

McKesson annual financial ratios
RatioFY 2026FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
P/E ratio (at fiscal year end)23.0426.5623.9814.2242.46—25.35688.59440.226.52
Price / sales0.270.240.230.180.180.130.100.110.140.17
Price / book——————4.452.842.992.95
Gross margin3.6%3.7%4.2%4.5%5.0%5.1%5.2%5.5%5.4%5.7%
Operating margin1.5%1.2%1.3%1.6%0.8%-2.1%1.1%0.4%0.4%3.6%
Net margin1.2%0.9%1.0%1.3%0.4%-1.9%0.4%0.0%0.0%2.6%
Free cash flow margin1.4%1.5%1.3%1.7%1.5%1.7%1.7%1.7%1.9%2.2%
Return on equity (ROE)——————17.7%0.4%0.7%45.7%
Return on assets (ROA)5.8%4.4%4.5%5.7%1.8%-7.0%1.5%0.1%0.1%8.3%
Debt / equity——————1.450.940.800.77
Current ratio0.850.900.920.920.951.030.991.021.011.04
Revenue growth12.4%16.2%11.7%4.8%10.8%3.1%7.8%2.9%4.9%4.0%
EPS growth49.2%14.9%-10.5%246.2%—-670.9%2,811.8%-46.9%-98.6%134.3%

Related